Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Increased to $645.00 by Analysts at Cowen

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) had its price objective upped by Cowen from $640.00 to $645.00 in a research report issued to clients and investors on Wednesday, Stock Target Advisor reports. Cowen’s price objective would suggest a potential downside of 10.25% from the stock’s previous close.

Other equities research analysts have also issued research reports about the stock. Bank of America lowered shares of Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and cut their target price for the company from $675.00 to $575.00 in a research note on Wednesday, January 5th. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $605.00 to $632.00 and gave the stock an “equal weight” rating in a research note on Tuesday, April 12th. Oppenheimer decreased their target price on shares of Regeneron Pharmaceuticals from $825.00 to $775.00 and set an “outperform” rating for the company in a research report on Tuesday, February 8th. Barclays upped their target price on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 12th. Finally, StockNews.com started coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, March 31st. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $724.63.

NASDAQ:REGN traded up $2.48 on Wednesday, reaching $718.70. The stock had a trading volume of 5,372 shares, compared to its average volume of 730,734. The company has a current ratio of 3.56, a quick ratio of 3.07 and a debt-to-equity ratio of 0.11. The company has a 50-day moving average of $664.52 and a 200 day moving average of $633.02. The stock has a market cap of $77.29 billion, a P/E ratio of 9.97, a price-to-earnings-growth ratio of 1.25 and a beta of 0.21. Regeneron Pharmaceuticals has a 12-month low of $478.40 and a 12-month high of $747.42.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last posted its quarterly earnings data on Friday, February 4th. The biopharmaceutical company reported $23.72 earnings per share for the quarter, beating analysts’ consensus estimates of $18.49 by $5.23. The company had revenue of $4.95 billion during the quarter, compared to analysts’ expectations of $4.49 billion. Regeneron Pharmaceuticals had a net margin of 50.24% and a return on equity of 55.11%. The firm’s revenue for the quarter was up 104.4% on a year-over-year basis. During the same period in the prior year, the company posted $8.72 EPS. On average, equities analysts predict that Regeneron Pharmaceuticals will post 45.17 EPS for the current year.

In other news, CFO Robert E. Landry sold 1,862 shares of the firm’s stock in a transaction on Monday, April 11th. The shares were sold at an average price of $734.06, for a total transaction of $1,366,819.72. Following the transaction, the chief financial officer now owns 28,744 shares in the company, valued at approximately $21,099,820.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bonnie L. Bassler sold 1,240 shares of the firm’s stock in a transaction on Thursday, April 7th. The shares were sold at an average price of $725.00, for a total transaction of $899,000.00. Following the transaction, the director now owns 1,082 shares in the company, valued at approximately $784,450. The disclosure for this sale can be found here. In the last quarter, insiders sold 44,459 shares of company stock valued at $30,177,797. Insiders own 10.76% of the company’s stock.

A number of large investors have recently bought and sold shares of REGN. Heritage Wealth Advisors acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $30,000. Benjamin Edwards Inc. acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $33,000. Delos Wealth Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $33,000. Byrne Asset Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $34,000. Finally, Evoke Wealth LLC grew its position in Regeneron Pharmaceuticals by 427.3% in the 3rd quarter. Evoke Wealth LLC now owns 58 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 47 shares during the last quarter. Institutional investors and hedge funds own 82.97% of the company’s stock.

About Regeneron Pharmaceuticals (Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading

Stock Target Advisor logo

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.